Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Allergic Reactions02:06

Allergic Reactions

Overview
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland.

BMC infectious diseases·2025
Same author

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.

The Journal of infection·2024
Same author

The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis-Interstitial Lung Disease in the European Scleroderma Trial and Research Database.

Diagnostics (Basel, Switzerland)·2024
Same author

Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.

EBioMedicine·2023
Same author

[Hymenoptera venom allergy: what's new in 2023].

Revue medicale suisse·2023
Same author

Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity.

Frontiers in immunology·2020
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

[Allergic rhinoconjunctivitis and immunotherapy: an update].

Annette Leimgruber1, François Spertini

  • 1Service d'immunologie et d'allergie, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|February 26, 2009
PubMed
Summary
This summary is machine-generated.

Allergic rhino-conjunctivitis significantly impacts quality of life and can lead to asthma or eye complications. New allergen immunotherapy approaches focus on safer, more effective treatments.

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Related Experiment Videos

Last Updated: Jun 25, 2026

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

Area of Science:

  • Allergology and Immunology
  • Ophthalmology
  • Pulmonology

Context:

  • Rhinitis and allergic conjunctivitis are common conditions with significant quality of life implications.
  • Untreated or improperly managed allergic rhino-conjunctivitis can lead to severe health issues, including asthma development and ocular complications.
  • Topical steroid use and delayed diagnosis of severe ailments pose additional risks.

Purpose:

  • To review current treatment strategies for allergic rhino-conjunctivitis.
  • To highlight recent advancements in allergen-specific immunotherapy (AIT).
  • To discuss the development of hypoallergenic formulations and novel adjuvants for improved AIT efficacy and safety.

Summary:

  • Current treatments for allergic rhino-conjunctivitis are reviewed, emphasizing the risks associated with disease progression and certain therapeutic agents.
  • Recent progress in allergen-specific immunotherapy is detailed, focusing on innovations aimed at enhancing treatment effectiveness and safety.
  • The development of hypoallergenic formulations and new adjuvants is crucial for minimizing systemic allergic reactions and improving treatment outcomes, potentially reducing treatment duration.

Impact:

  • Improved management of allergic rhino-conjunctivitis, reducing its impact on patients' quality of life.
  • Potential for earlier intervention and prevention of severe associated conditions like asthma and ocular complications.
  • Advancements in AIT offer more effective and safer therapeutic options, potentially leading to long-term tolerance and reduced disease burden.